The E3/19K glycoprotein of adenovirus functions to diminish recognition of adenovirus-infected cells by major histocompatibility complex class I-restricted cytotoxic T lymphocytes (CTLs) by binding intracellular class I molecules and preventing them from reaching the plasma membrane. In the present study we have characterized the nature of the interaction between E3/19K and the H-2K d (K d) molecule. An E3/19K molecule genetically engineered to terminate six residues from its normal COOH terminus (AE19), was found to associate with K d in a manner indistinguishable from wild-type E3/19K. Unlike E3/19K, however, AE19 was transported through the Golgi complex to the plasma membrane, where it could be detected biochemically and immunocytochemically using a monodonal antibody specific for the lumenal domain of E3/19K. Importantly, AE19 also differed from E3/19K in being unable to prevent the presentation of Ka-restricted viral proteins to CTLs. This is unlikely to be due to AE19 having a lower avidity for K d than E3/19K, since AE19 was able to compete with E3/19K for K a binding, both physically, and functionally in nullifying the E3/19K blockade of antigen presentation. These findings indicate that the ability of E3/19K to block antigen presentation is due solely to its ability to retain newly synthesized class I molecules in the endoplasmic reticulum.
M
HC class I-restricted CTLs recognize virus-infected cells and release soluble factors that either lyse the cell or have direct or indirect antiviral activities. The specificity of triggering this response is conferred by the TCR, which binds class I molecules on the virus-infected cell complexed to linear determinants from viral proteins. Under normal conditions, these determinants are derived from newly synthesized viral proteins present in the cytosol of virus-infected cells (1) (2) (3) .
Perhaps the most compelling evidence that CTLs are able to reduce the reproductive capacity of viruses is the existence of viral proteins, nonessential to viral replication, that diminish the presentation of viral antigens to CTLs. The best characterized of these proteins is the E3/19K glycoprotein (E19) encoded by some adenovirus serotypes. E19 is a resident endoplasmic reticulum (ER) 1 glycoprotein expressed early in adenovirus infection that forms a tight complex with most human MHC class I allomorphs, preventing them from reaching the cell surface. This prevents CTLs from recognizing viral proteins synthesized after synthesis of El9 has commenced (4-6), presumably because antigens processed from the cytosol must associate with newly synthesized class t Abbreviations used in this paper: BFA, brefeldin A; ER, endoplasmic reticulum; GC, Golgi complex; HA, hemagglutinin; NP, nucleoprotein; NS1, nonstructural 1; PB2, basic polymerase 2; Vac, vaccinia virus.
I molecules in an intracellular location (7) (8) (9) . The retention of E19 in the ER requires the presence of the six amino residues that constitute its cytosolic COOH terminus. These residues (DEKKMP) act as a positive signal for ER retention, since their transfer to the COOH terminus of other type I-anchored membrane glycoproteins confers ER retention (10) .
Although adenovirus is a human pathogen, E19 can also bind some mouse class I MHC allomorphs (11) . This is not totally unexpected given the close sequence homology between human and mouse class I molecules. The differential binding of El9 to mouse class I aUomorphs has been exploited to determine that residues in or near the antigen binding groove of class I molecules can influence the ability of E19 to bind class I molecules in the ER (12, 13) . This finding raises the possibility that E19 binds to this region of class I molecules, and perhaps prevents antigen association with dass I molecules.
Previously, we showed that mouse ceils infected with a vaccinia virus (Vac) recombinant expressing the E19 glycoprotein exhibit a deficit in presentation of newly synthesized proteins in association with some mouse class I allomorphs. The extent of the deficit correlated with the degree to which the allomorphs co-precipitated E19 from detergent extracts of 35S-methionine-labeled cells, and was most pronounced with K a, which bound El9 in an equimolar complex (6) , and failed to reach the cell surface. These findings indicated that proteins processed by the cytosolic processing pathway associate with newly synthesized class I molecules during their transport to the cell surface.
In the present study we further characterize the interaction of EI9 with class I molecules. We have produced a vaccinia virus (Vac) recombinant expressing a truncated El9 molecule that is not retained in the EP,, but maintains a high affinity for K a. Using this recombinant we show that the truncated E19 does not block the exocytosis of class I molecules, and does not affect the presentation of viral antigens processed by the cytosolic route. Monoclonal Anti-E19 Antibody. Splenocytes derived from BALB/cByJ mice (The Jackson Laboratory, Bar Harbor, ME), immunized first with sonicated E19-Vac (6) -infected mouse spleen cells and 3 wk later with sonicated adenovirus 5-infected human KB cells, were fused with SP2 myeloma cells. An E19-specific antibody-producing hybridoma was identified by immunoperoxidase screening of E19-Vac-infected cells. After cloning, this hybridoma (Twl.3) continued to produce an antibody of the 3'3 subtype that specifically precipitated both E19 and AE19 (Fig. 1 b) .
Materials and Methods

Cells and
Immunofluorescence and Cytofluorography. For cytofluorography, cells were infected with Vac recombinants for 4 h at 37~ Viable cells or cells fixed and permeabilized by brief incubation with 70% ethanol were washed twice and incubated with mAb diluted in PBS, 1% BSA, 1% azide at 4~ for 40 rain. Cells were then washed twice with PBS, incubated at 4~ for 40 min with fluoresceinconjugated rabbit anti-mouse Ig (Dako Corp., Carpinteria, CA), washed twice, and their fluorescence quantitated using an Epics cytofluorograph (Coulter Electronics, Hialeah, FL). For immunofluorescence microscopy, infected P815 cells were centrifuged onto acid-cleaned D-mm glass coverslips in a 24-well plate. After air drying, cells were fixed for 20 rain in 0.5% (wt/vol) paraformaldehyde and permeabilized by the addition of 0.1% (wt/vol) saponin during all subsequent incubations. For colocalization studies with Con A, ceils were incubated for 90 win at 40C with Twl.3, washed twice, and incubated for 90 min at 4~ with fluorescein-conjugated rabbit anti-mouse Ig alone or with rhodamine-conjugated Con A. For double immunofluorescence studies, cells were incubated with a rabbit antisera raised to MG160, a resident protein of the medial Golgi complex (GC) (14, 15) , followed by fluoresceinconjugated goat anti-rabbit IgG. To block free antibody binding sites on the goat antibody, rabbit serum was added for 10 rain at room temperature, followed by Twl.3 anti-E19 antibody culture supematant diluted 1:3. Finally, rhodamine-conjugated anti-mouse IgG was added. Coverslips were mounted in Mowiol-PBS containing 5% (wt/vol) 1,4 diazabicyclo[2.2.2]octane to retard fading. Cells were examined using an Axiopliot photomicroscope (Carl Zeiss, Inc., Thoruwood, NY) equipped with appropriate filters to gate red and green fluorescence. Images obtained with a 100x planneofluor objective were captured with a video camera (C2400-08 SI'I~ Hamamatsu, Hamamatsu City, Japan). After digital processing with an image processor (DVS-3000; Hamamatsu), the images were transferred to a Macintosh II computer and further enhanced in the Macintosh II using the Adobe Photoshop program to change eight-bit grey scale images into eight-bit red or green images. The images were then printed separately or superimposed using a Sony Mavigraph color video printer.
Construction ofVaccinia Recombinants.
To produce AE19-Vac, two synthetic oligonucleotides were used, a 30-base 5' primer corresponding to nucleotide 1394-1414 of the published E19 sequence (16) and encoding a SalI digestion site and Kozac sequence (17) , and a 34-base 3' primer corresponding to E19 nucleotide 1856-1875 followed by nucleotides encoding two stop codons, Nod restriction site, and then 10 nucleotides corresponding to El9 nucleotide 1876-1885. Primers were used in the PCR using the pJC1 plasmid (6) containing the E19 gene. The PCR product was gel purified and digested with SalI and NotI restriction enzymes, and ligated into the SalI-NotI site of a derivative of pSC.11 modified to contain these sites to allow directional ligations (L. E. Eisenlohr, manuscript submitted for publication). Vaccinia recombinants were produced using this plasmid as described (6) . The sequence of the AE19-Vac was confirmed by DNA sequence analysis of the plasmid DNA corresponding to the entire AE19 gene (data not shown).
Cell Labeling and Immunoprecipitation. Cells infected with vaccinia recombinants were incubated in methionine-free medium for 30 rain at 37~ and radiolabeled for 10 rain at 37~ by incubating cells at a concentration of 107 cells/ml with 100-200/zCi 35S-methionine (Amersham Corp., Arlington Heights, IL). In pulsechase experiments, cells were incubated after radiolabeling with medium supplemented with 5 mg/ml methionine for the indicated times at 37~ For each sample, at least 2 x 106 labeled cells were lysed in PBS (pH 8.0), containing 0.5% NP-40, 1 mM PMSF at 4~ for 20 rain. Extracts were centrifuged at 15,000 g and the supernatants incubated with protein A-Sepharose beads (Pierce Chemical Co., Rockford, IL) loaded with mAbs. Half of the immunoprecipitates were digested overnight at 32~ with endo H (Boehringer Mannheim Biochemicals, Indianapolis, IN). Immunopredpitates were analyzed on 12% polyacrylamide gels using the buffer system of Laemmli (18) . Gels were fixed and incubated with Amplify (Amersham Corp.) before drying under vacuum. Dried gels were exposed to preflashed Kodak XAR-5 film at -70~ Cytotoxicity Assay. P815 (2 x 106) cells were infected with vaccinia recombinants for 3 h and labeled for 1 h with NaSlCrO4 (Amersham Corp.). Radiolabeled cells were incubated for 4 h at 37~ with antiinfluenza effector cells. Effector cells were obtained from cultures of splenocytes from influenza A/Puerto Rico/8/34 (H1N1) (PR8) hemagglutinin (Hl-vac), nudeoprotein (NP-vac), nonstructural 1 (NSl-vac), or basic polymerase 2 (PB2-vac) recombinant vac-immunized BALB/cByJ mice restimulated in vitro with PR8 (19) . The amount of 51Cr released into the medium was determined by gamma radiation counting. Lysis of uninfected target cells ranged from 2 to 18% and was subtracted from all values. Experimental values represent the average of the triplicates; all values had a SEM of <4% of the specific release. The percent 5~Cr release was calculated as follows: 100x [(experimental cpm -spontaneous [no splenocytes] cpm)/(total [detergent] cpm -spontaneous cpm)]. Spontaneous release values were always <25% of total release.
Lactoperoxidase Iodination. Cells (107) infected with vac recombinants for 6-7 h were washed three times in PBS and resuspended in 0.8 ml PBS supplemented with 5 ram glucose, 1 mCi Na~ZSI (New England Nuclear, Boston, MA), 1 U/m1 hctoperoxidase, and 5 U/ml glucoseoxidase. After a 5-15-rain incubation at room temperature, an additional 1 U/ml lactoperoxidase and 5 U/m1 glucoseoxidase was added. Cells were then incubated for a further 15 rain at room temperature, washed twice in PBS, 10 mM NaI, lysed in extraction buffer, and the extracts immunoprecipitated as described above.
Results
Production and Characterization of AE19-Vac and an E19-specific mA~
To examine whether E19 blocks antigen assodation with K d requires the uniform expression of high levels of E19 nonconstitutively in target cell populations. The expression vector most suited for this purpose is Vac, which also provides the advantage of allowing coexpression of additional foreign proteins by simply co-infecting cells with multiple Vac recombinants. We therefore constructed a Vac recombinant that expresses an E19 glycoprotein without the six COOH-terminal amino acids required for ER retention (AE19-Vac). A rabbit antiserum raised to a synthetic peptide corresponding to the 15 COOH-terminal amino acids of El9 that effidently precipitates E19 failed to precipitate AE19 from 3SS-methionine-labded AE19-Vac-infected P815 cells (Fig. 1  a) . This confirmed that the COOH terminus was altered in AE19, and indicated that we could not use this antiserum to characterize AE19-Vac. To detect AE19 we produced a B cell hybridoma (Twl.3) secreting a mouse mAb of the 3,3 subtype that recognized both El9 and AEt9 (see Materials and Methods). As seen in Fig. 1 b, the Twl.3 mAb precipi- tated both E19 and AE19 from detergent extracts of 35S-methionine-labeled AE19-Vac and E19-Vac-infected ceils, respectively, as determined by SDS-PAGE analysis of precipitates. This also revealed that AE19 migrated slightly faster than E19, which is consistent with its COOH-terminal deletion. The antibody is specific for the lumenal domain of E19, since, as described brow, it binds to viable cells expressing AE19 on the plasma membrane.
The Twl.3 mAb precipitated from E19-Vac-infected cell extracts an additional protein with an apparent molecttlar mass of 88 kD (Fig. 1 c, lane 3) . This is a cellular protein, since it was also speeificaUy precipitated from uninfected cells (Fig.  1 c, lane 2) . It is potentially of great interest as it could represent a cellular homologue of E19. We have not been able, however, to demonstrate that this protein interacts with class I molecules, since class I molecules do not co-precipitate with the protein (the expected location of class I heavy chains can be determined from comparison with lane I, which represent immunoprecipitation with a Ka-spedfic mAb), even after chemical crosslinking of detergent extracts (not shown). It does not represent the 88-kD class I-associated protein identified by Degen and Williams (20) Immunolocalization of El9 and AE19. The cdlular localization of AE19 and E19 in Vac recombinant-infected P815 ceUs was examined using the Twl.3 mAb in indirect double immunofluorescence of fixed and permeabilized calls attached to coverslips. In E19-vac-infected cells, the Twl.3 mAb stained the nuclear membrane and cytoplasmic structures (Fig. 2 a, left, red staining). A similar pattern was observed using rhodamine-Con A, which predominantly stains the ER by virtue of it specificity for terminal mannose residues ( Fig.   2 a, right, green staining) . The staining of Twl.3 and Con A was largely co-incident as indicated by the yeUow color obtained when superimposing the two images (Fig. 2 a, middle). To determine if E19 was also present in the GC, cells were double stained with Twl.3 and a rabbit antiserum specific for a resident protein of the medial GC (14, 15) . The GC in P815 cells centrifuged onto coverslips appears as smaU green punctate structures (Fig. 2, b and c, right) . Little of this stain colocalized with TW1.3 in E19-Vac-infected cells (Fig. 2 b, middle). By contrast, TW1.3 clearly colocalized with the anti-GC antiserum (Fig. 2 c, middle) in AE19-Vac-infected cells, in addition to staining the ER (Fig. 2 c, left) . This analysis suggested that while E19 was restricted to pre-GC compartments, AE19 was transported to the GC.
To quantitatively determine whether AE19 was transported to the cell surface, L929 cells were infected with E19-Vac or AE19-Vac for 5 h, stained with Twl.3, and analyzed using a cytofluorograph (Table 1) . Using viable cells, Twl.3 bound above background levels to AE19-Vac-, but not E19-Vac-infected cells. The failure to detect E19 on E19-Vac-infected cells is Biochemical Analysis of A E19 Intracellular Transport and Binding to K a. To biochemically characterize the intracellular trafficking of E19 and AE19, 3SS-methionine pulse-labeled P815 cells were chased for various times at 37~ detergent extracted, and immunoprecipitated with Twl.3 anti-E19 mAb or with an anti-H-2K d mAb. Before analysis by SDS-PAGE, half the samples were treated with endo H to remove the simple oligosaccharides characteristic of glycoproteins before they are modified by enzymes that reside in the medial GC. Deglycosylation by endo H results in an easily detectable increase in the mobility of K s and E19 in SDS-PAGE, and indicates proteins in a post-ER compartment. The resistance of proteins to this mobility shift suggests that they have been transported to or through the medial GC.
Immediately after pulse-labeling, AE19 was completely sensitive to endo H digestion (Fig. 3) . With increasing times after the pulse, a subpopulation of AE19 became less sensitive to digestion with endo H, indicating that at least a portion the AE19 can transit through the Golgi. As is typical of proteins with mature oligosaccharides, endo H-resistant AE19 migrated with slightly lower mobility than AE19 with less mature oligosaccharides. In contrast, all the newly synthesized El9 remained sensitive to endo H digestion over the entire 8-h chase period (Fig. 3) . Immunoprecipitation of detergent lysates with anti-K d revealed that newly synthesized AE19, like E19, complexed within the 10-min pulse to newly synthesized K a, and remained bound in an m1:1 ratio over the 4-h pulse period (Fig.  4) . fl2-microglobulin was co-precipitated from both E19-Vacand AE19-Vac-infected cells in increasingly greater quantities after labeling. Most importantly, K a synthesized in E19-Vacinfected cells remained sensitive to endo H digestion over the 4-h chase, while K d precipitated from AE19-Vac became endo H resistant beginning within 30 min after labeling, and increasingly over the next 3.5 h. K a in cells infected with a control Vac recombinant became almost completely resistant to endo H digestion within 1 h of synthesis (not shown). Since similar amounts of K d and E19 were precipitated from E19-Vac-and AE19-Vac-infected cells, these findings strongly suggest that K d associated with AE19 is transported through the GC.
To further examine the surface expression of E19 and AE19, cells were surface iodinated 7 h after infection with AE19-Vac and detergent extracts immunoprecipitated with the Twl.3 mAb. Immunoprecipitates were then treated with endo H or left untreated, and analyzed by SDS-PAGE. As seen in Fig. 5 , iodinated AE19 was easily detected by this method. To determine whether this labeled pool of AE19 was truly present on the cell surface and not in an intracellular location, AE19-Vac-infected cells were incubated with brefeldin A (BFA) to prevent the surface expression of AE19 (8) . In this case far less AE19 was iodinated. This was due to the intracellular location of AE19 in these cells, not low levels of AE19 expression, since labeling of AE19 was completely restored by removing the BFA and incubating cells for 60 min at 37~ in the presence of protein synthesis inhibitors to prevent synthesis of additional AE19. It can also be seen in Fig. 5 that only low levels of E19 were radioiodinated on E19-Vac-infected cells. This almost certainly represents intra- Figure 5 . SurfaceiodinationofAE19. P815cellsinfectedwithVacrecom-binants for 6-7 h were surface radioiodinated using lactoperoxidase. Cells were incubated where indicated with BFA from the time of infection. In the last two lanes, BFA was removed from cells that were incubated for another 1 h at 37~ in the presence of anisomycin at 25 #g/ml to block additional protein synthesis. Detergent lysates were immunoprecipitated using protein A-Sepharose beads that had been preloaded with Twl.3 anti-E19 mAb. Immunoprecipitates were digested with endo H as indicated, and analyzed by SDS-PAGE. cellular E19, since similar amounts of E19 were radioiodinated in E19-Vac cells treated with BFA. Thus, these findings confirm that E19 is confined to intracellular compartments, while AE19 is able to reach the cell surface.
In addition to a major band migrating with the mobility expected for AE19, a minor radioiodinated species migrating with a mobility intermediate between glycosylated and deglycosylated E19 was precipitated by Twl.3 (marked in Fig.  5 by an asterisk). A band of a similar mobility was apparent at early chase times in 3SS-methionine-labeling experiments (Fig. 3) . The disappearance of this band upon endo H treatment of 3SS-methionine-labeled lysates (Fig. 3) suggests that this species represents AE19 containing only one of the two oligosaccharides normally added to E19.
Treatment of radioiodinated AE19 immunoprecipitates resulted in three bands, corresponding to AE19 with two, one, or zero oligosaccharides. Note that endo H-treated AE19 with a single oligosaccharide migrated with a lower mobility than the adjacent band in the non-endo H-treated lane, which is consistent with expected mobility difference between AE19 with a mature vs. immature oligosaccharide. This mobility difference indicates that this species is derived from AE19 containing two oligosaccharides. At least a portion of AE19 completely deglycosylated by endo H must also be derived from AE19 containing two oligosaccharides since there is more of this material than of the singly glycosylated, non-endo H-treated AE19. Thus, AE19 is able to reach the cell surface with one or both of its oligosaccharides in immature form. (19). We previously found that co-infection of cells with E19-Vac and Vac recombinants expressing the individual viral proteins results in complete inhibition of presentation of HA and NP, partial inhibition of NS1, and very slight inhibition of PB2. To establish whether the AE19 protein behaved in a similar fashion, we repeated this experiment using AE19-Vac and CTL specific for the individual influenza virus antigens. AE19 did not inhibit the presentation of any of the influenza virus antigens, since cells co-infected with AE19-Vac were lysed at similar levels as cells co-infected with a control Vac recombinant expressing a protein from respiratory syncytial virus (Table 2 ). In the same experiment, E19 behaved as previously observed, efficiently blocking presentation of Kd-restricted HA and NP, partially blocking Ld-restricted NS-1, and not affecting Da-restricted PB2. A trivial explanation for the failure of AE19 to block antigen presentation of HA and NP is that it forms a more tenuous complex with K a than does E19. Although this did not seem likely based on the equal co-precipitation of E19 and AE19 with K d, it was important to demonstrate that AE19 could compete with E19 for binding of K a, nullifying the E19 blockade of antigen presentation. This was accomplished by co-infecting cells with E19-Vac, AE19-Vac, and Vac recombinants expressing HA or NP. As seen in Table 3 , coinfection with AE19-Vac completely restored the presentation of HA or NP. The recovery of antigen presentation is specifically mediated by AE19, and is not simply attributable to the effects of Vac superinfection, since co-infection with a similar dose of a control Vac recombinant had no effect on antigen presentation. Thus, these finding suggest that El9 does not block antigen association with dass I molecules.
Expression of AEl9 Protein Does Not
Intracellular Dimerization of El9 and AE19.
It is likely that E19 exists in cells as multimers, since a subpopulation mi- grates as dimers when analyzed in SDS-PAGE under nonreducing conditions. It was therefore possible that the effect of AE19 on E19-mediated blockade of antigen presentation was due to the formation of mixed dimers unable to bind to K a. To examine this possibility, we characterized the ability of El9 and AE19 to form mixed dimers. In P815 ceils infected with E19-Vac or AE19-Vac alone, the monomeric and dimeric forms of the respective proteins precipitated by Twl.3 from pulse-labeled extracts could be completely distinguished from each other based on the higher mobility of AE19 (Fig.  6 a) . In cells co-infected with equal doses of E19-Vac and AE19-Vac, a third band, presumably a heterodimer, was present halfway between the observed bands of the E19 and AE19 directs. The heterodimer was more dearly visible after deglycosylation by endo H digestion, which is expected since oligosaccharides generally decrease the sharpness of protein migration in SDS-PAGE. The proportion of each of the species in cells infected under these conditions, or with 10-fold excess of one of the recombinants, approximates a binomial distribution of the three species, which suggests that E19 and AE19-Vac randomly associate with each other.
In parallel, extracts prepared from co-infected cells were immunoprecipitated with a Ka-specific mAb (Fig. 6 b) . Both monomeric and dimeric forms of the E19 and AE19 were co-precipitated with K a. Most importantly, heterodimers formed between the E19 and AE19 protein were also present, and therefore are fully capable of binding to class I molecules. Therefore, the observed competition between AE19 and E19 in blocking antigen presentation cannot be ascribed to the formation of heterodimers incapable of binding to K d.
Discussion
The goal of the present study was to determine whether El9 blocks the association of antigen with class I molecules. Our strategy was to engineer a modified El9 glycoprotein that maintains its binding to class I molecules but is no longer retained in the ER. It had been shown previously that retention of El9 in the ER could be abrogated by altering residues in the COOH terminus of El9, a portion of the molecule that is believed to reside in the cytosol (22, 23) . As removal of the entire cytosolic domain of El9 was found to reduce its binding to class I molecules (24) , it was important to make a less severe alteration. There is some controversy regarding the exact features of cytosolic domain that confer ER retention. A recent report, however, clearly demonstrated that transfer of the six terminal residues of El9 to other membrane glycoproteins greatly retarded their exit from the ER (10). We therefore decided to delete only the six terminal residues from El9 in creating the AE19 protein.
By immunochemical and biochemical analysis, we demonstrated that AE19 is transported to the plasma membrane, confirming the importance of the cytosolic COOH-terminal residues in mediating EP, retention. Some of the cell surface AE19 contained carbohydrates sensitive to digestion with endo H. This indicates either that the oligosaccharides are partially resistant to modification by enzymes in the GC, or that a subpopulation of AE19 does not traverse the entire GC. The existence of surface AE19 with one endo H-sensitive and one endo H-resistant oligosaccharide indicates that the first mechanism accounts for some, if not all, of the oligosaccharide heterogeneity. The failure of GC enzymes to modify AE19 oligosaccharides is probably unrelated to its association with class I molecules, since we have observed a similar heterogeneity in L929 cells, which do not have class I molecules that tightly associate with AE19 or E19 (our unpublished results). Observations of similar heterogeneity in secreted forms of E19 expressed by insect cells, which do not possess MHC genes, support this conclusion (25) . Instead, it is more likely that failure of GC enzymes to modify AE19-associated oligosaccharides is due to an intrinsic limit to their accessibility, perhaps because they are located in a more internal position after the assembly of AE19 into oligomers.
The maturation of E19-associated oligosaccharides, while incomplete, still serves as a measure of E19 export from the ER. By this criteria, AE19 is transported relatively slowly from the ER, with a half time of "~4 h. The half time of K d acquisition of endo H resistance in AE19-Vac-infected cells demonstrated similar kinetics. This represents an ~10-fold increase over the half time of K d export in Vac-infected cells, and indicates that AE19 remains complexed with K a at least until K a has passed through the medial GC.
This latter point bears on a question central to the interpretation of the inability of AE19 to block antigen presentation: how tight is the association of AE19 with K d in the compartment where antigen association normally occurs? Two findings suggest that AE19 binds K d with a similar avidity as E19 in early e.xocytic compartments. First, similar amounts of E19 and AE19 co-precipitate with K d. Second, AE19 is able to compete with E19 both biochemically for K d binding, and functionally, to reverse the effect of E19 on antigen presentation. Thus, it appears that AE19 binds to K a with high affinity at least until the complex has passed through the medial GC. The stability of the complex during the latter stages of exocytosis remains to be established. As it is believed that antigens associate with class I molecules in an exocytic compartment proximal to the medial GC (6-9), it seems unlikely that the possible dissociation of AE19 from K a in a late exocytic compartment would account for its failure to block antigen association. Ultimately, however, to definitively establish whether E19 blocks association of antigen with class I molecules will require direct examination of the peptide binding capacity of E19-class I complexes.
If AE19 remains in a tight complex with class I molecules at the cell surface, this would mean that E19 binding does not interfere with the interaction of class I molecules with the TCR. This would suggest that class I heavy chains are able to interact with at least four proteins simultaneously, the TCR, CDS, B2-microglobulin, and E19. In this case, as the polymorphic residues in the o~2 domain that influence the affinity of E19 for mouse class I molecules are likely to be in close proximity to the TCR, it would further imply that these residues do not contact E19, but act by inducing conformational alterations in other regions of the heavy chain.
A recent study determined that E19 binding and rapid export from the ER of a series of Kd-K k chimeric molecules coordinately mapped to five polymorphic residues in the first half of the c~2 domain (13) . Based on this finding, it was proposed that E19 interferes with class I export by either affecting class I assembly, or by interfering with the interaction of class I molecules with accessory molecules that positively influence class I transport. Given the apparently normal binding of AE19 to K d, the transport of AE19-K d complexes to the cell surface and their recognition by CTL strongly argue that E19 blocks class I transport solely by virtue of its cytosolic ER retention sequence.
If E19 binds to class I molecules in a fundamentally different manner than CD8, B2-microglobulin, antigenic peptides, or the TCR, from which cellular gene is E19 derived? E19 appears to have its origins among the Ig superfamily of genes, with whose members it shares a tenuous homology (26) . Protein or DNA sequence analysis of the 88-kD protein that reacts with the Twl.3 mAb could reveal that it is the cellular homologue of E19. Although this protein has no apparent role in class I assembly or transport, there is no guarantee that cellular descendents of the E19 ancestor will have any such function.
There are three general possibilities for the function of the modern cellular descendent(s) of the putative E19 ancestor. It might have nothing to do with class I assembly and transport, it might be one of the gene products known (20) or suspected (27) to interact with class I during exocytosis, or its interaction with class I genes could remain to be characterized. Regarding the latter possibility, it is clear that we are only beginning to understand the subtleties in the assembly and transport of class Ia molecules. Furthermore, the MHC encodes many class Ib molecules whose characteristics and functions are unknown, and that probably interact with a number of undiscovered MHC and non-MHC gene products, one of which could be descended from the progenitor of E19.
